Research progress on chronic obstructive pulmonary disease with bronchiectasis

doi:10.19983/j.issn.2096-8493.20230093

Abstract

Abstract:

Chronic obstructive pulmonary disease (COPD) is a heterogeneous pulmonary condition and a common chronic respiratory disease with high morbidity and mortality. Bronchiectasis is a recurring pyogenic infection caused by various causes, resulting in repeated damage and/or obstruction of the small and medium bronchus, the destruction of the bronchial wall structure, bronchial abnormalities and persistent dilation. Bronchodilatation-chronic obstructive pulmonary disease overlap syndrome (BCOS) is a combination of bronchiectasis and COPD in the same patient. BCOS is a common clinical syndrome, but there are few studies on the clinical characteristics and prognosis of BCOS. Through a large number of literature retrieval and analysis, this review comprehensively expounds the latest mechanism research, clinical characteristics research, and related risk and prognosis research progress of COPD complicated with bronchiectasis, aiming at a clearer understanding of this syndrome and providing new ideas for clinical prevention and treatment of BCOS.

Key words: Pulmonary disease, chronic obstructive, Bronchiectasis, Review literature as topic

CLC Number:

Dai Zhongshang, Zhong Yanjun, Chen Yan. Research progress on chronic obstructive pulmonary disease with bronchiectasis[J]. Journal of Tuberculosis and Lung Disease , 2023, 4(6): 499-505. doi: 10.19983/j.issn.2096-8493.20230093

References 76

[1]	Agustí A, Celli BR, Criner GJ, et al. Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. Eur Respir J, 2023, 61(4):2300239. doi:10.1183/13993003.00239-2023.
[2]	GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990—2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, 2015, 385(9963):117-171. doi:10.1016/S0140-6736(14)61682-2.
[3]	Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, 2012, 380(9859):2095-2128. doi:10.1016/S0140-6736(12)61728-0. pmid: 23245604
[4]	GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990—2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med, 2017, 5(9):691-706. doi:10.1016/S2213-2600(17)30293-X.
[5]	GBD Chronic Respiratory Disease Collaborators. Prevalence and attributable health burden of chronic respiratory diseases, 1990—2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Respir Med, 2020, 8(6):585-596. doi:10.1016/S2213-2600(20)30105-3.
[6]	Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. Lancet, 2018, 391(10131):1706-1717. doi:10.1016/S0140-6736(18)30841-9. pmid: 29650248
[7]	Yin P, Wang H, Vos T, et al. A subnational analysis of mortality and prevalence of COPD in China from 1990 to 2013: findings from the global burden of disease study 2013. Chest, 2016, 150(6):1269-1280. doi:10.1016/j.chest.2016.08.1474.
[8]	支气管扩张症专家共识撰写协作组, 中华医学会呼吸病学分会感染学组. 中国成人支气管扩张症诊断与治疗专家共识. 中华结核和呼吸杂志, 2021, 44(4):311-321. doi:10.3760/cma.j.cn112147-20200617-00717.
[9]	Quint JK, Millett ER, Joshi M, et al. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study. Eur Respir J, 2016, 47(1):186-193. doi:10.1183/13993003.01033-2015. pmid: 26541539
[10]	Monteagudo M, Rodríguez-Blanco T, Barrecheguren M, et al. Prevalence and incidence of bronchiectasis in Catalonia, Spain: A population-based study. Respir Med, 2016, 121:26-31. doi:10.1016/j.rmed.2016.10.014. pmid: 27888988
[11]	Weycker D, Hansen GL, Seifer FD. Prevalence and incidence of noncystic fibrosis bronchiectasis among US adults in 2013. Chron Respir Dis, 2017, 14(4):377-384. doi:10.1177/1479972317709649.
[12]	Mao B, Lu HW, Li MH, et al. The existence of bronchiectasis predicts worse prognosis in patients with COPD. Sci Rep, 2015, 5:10961. doi:10.1038/srep10961. pmid: 26077673
[13]	周玉民, 王辰, 姚婉贞. 等. 我国7省市城区40岁及以上居民支气管扩张症的患病情况及危险因素调查. 中华内科杂志, 2013, 52(5):379-382. doi:10.3760/cma.j.issn.0578-1426.2013.05.006.
[14]	Hurst JR, Elborn JS, De Soyza A. COPD-bronchiectasis overlap syndrome. Eur Respir J, 2015, 45(2):310-313. doi:10.1183/09031936.00170014. pmid: 25653262
[15]	Kim DN, Lazarus AA. Management of bronchiectasis. Dis Mon, 2008, 54(8):540-546. doi:10.1016/j.disamonth.2008.05.003. pmid: 18638622
[16]	Ni Y, Shi G, Yu Y, et al. Clinical characteristics of patients with chronic obstructive pulmonary disease with comorbid bronchiectasis: a systemic review and meta-analysis. Int J Chron Obstruct Pulmon Dis, 2015, 10:1465-1475. doi:10.2147/COPD.S83910.
[17]	Dal Negro RW, Bonadiman L, Turco P. Prevalence of different comorbidities in COPD patients by gender and GOLD stage. Multidiscip Respir Med, 2015, 10(1):24. doi:10.1186/s40248-015-0023-2.
[18]	Blasi F, Chalmers JD, Aliberti S. COPD and bronchiectasis: phenotype, endotype or co-morbidity? COPD, 2014, 11(6):603-604. doi:10.3109/15412555.2014.974744. pmid: 25384083
[19]	Agusti A, Calverley PM, Celli B, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res, 2010, 11(1):122. doi:10.1186/1465-9921-11-122.
[20]	Izquierdo M, Marion CR, Genese F, et al. Impact of Bronchiec-tasis on COPD Severity and Alpha-1 Antitrypsin Deficiency as a Risk Factor in Individuals with a Heavy Smoking History. Chronic Obstr Pulm Dis, 2023, 10(3):199-210. doi:10.15326/jcopdf.2023.0388. pmid: 37199731
[21]	Nigro E, Mosella M, Daniele A, et al. Adiponectin Increase in Patients Affected by Chronic Obstructive Pulmonary Disease with Overlap of Bronchiectasis. Life (Basel), 2023, 13(2):444. doi:10.3390/life13020444.
[22]	Tiew PY, Jaggi TK, Chan LLY, et al. The airway microbiome in COPD, bronchiectasis and bronchiectasis-COPD overlap. Clin Respir J, 2021, 15(2):123-133. doi:10.1111/crj.13294. pmid: 33063421
[23]	Huang JT, Cant E, Keir HR, et al. Endotyping Chronic Obstructive Pulmonary Disease, Bronchiectasis, and the “Chronic Obstructive Pulmonary Disease-Bronchiectasis Association”. Am J Respir Crit Care Med, 2022, 206(4):417-426. doi:10.1164/rccm.202108-1943OC.
[24]	Tiew PY, Lim AYH, Keir HR, et al. High Frequency of Allergic Bronchopulmonary Aspergillosis in Bronchiectasis-COPD Overlap. Chest, 2022, 161(1):40-53. doi:10.1016/j.chest.2021.07.2165.
[25]	Martinez-Garcia MA. Inhaled Corticosteroids and Bronchiectasis: Friend or Foe? J Clin Med, 2023, 12(9):3322. doi:10.3390/jcm12093322.
[26]	Ronco R, Franco G, Monzio Compagnoni M, et al. Healthcare costs and resource utilisation in bronchiectasis, asthma and COPD. ERJ Open Res, 2023, 9(4):00158-2023. doi:10.1183/23120541.00158-2023.
[27]	Baig SH, Stephen MJ. Outcomes of hospitalized patients with COPD exacerbation with bronchiectasis compared to COPD exacerbation and bronchiectasis exacerbation patients. Am J Med Sci, 2023, 366(1):76-78. doi:10.1016/j.amjms.2023.04.001.
[28]	Ni Y, Shi G, Yu Y, et al. Clinical characteristics of patients with chronic obstructive pulmonary disease with comorbid bronchiectasis: a systemic review and meta-analysis. Int J Chron Obstruct Pulmon Dis, 2015, 10:1465-1475. doi:10.2147/COPD.S83910.
[29]	Schiebler ML, Seo JB. Artificial Intelligence Analysis of Bronchiectasis Is Predictive of Outcomes in Chronic Obstructive Pulmonary Disease. Radiology, 2023, 307(1):e222675. doi:10.1148/radiol.222675.
[30]	Chalmers JD, Goeminne P, Aliberti S, et al. The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med, 2014, 189(5):576-585. doi:10.1164/rccm.201309-1575OC.
[31]	Sever ZK, Bircan HA, Sirin FB, et al. Serum biomarkers in patients with stable and exacerbated COPD-bronchiectasis overlap syndrome. Clin Respir J, 2020, 14(11):1032-1039. doi:10.1111/crj.13238.
[32]	Martínez-García Má, Méndez R, Olveira C, et al. The U-Shaped Relationship Between Eosinophil Count and Bronchiectasis Severity: The Effect of Inhaled Corticosteroids. Chest, 2023, 164(3):606-613. doi:10.1016/j.chest.2023.04.029. pmid: 37088355
[33]	Bafadhel M, Umar I, Gupta S, et al. The role of CT scanning in multidimensional phenotyping of COPD. Chest, 2011, 140(3):634-642. doi:10.1378/chest.10-3007. pmid: 21454400
[34]	Kim SH, Yang B, Yoo JY, et al. Clinical characteristics, radiological features, and disease severity of bronchiectasis according to the spirometric pattern. Sci Rep, 2022, 12(1):13167. doi:10.1038/s41598-022-17085-3.
[35]	Patel IS, Vlahos I, Wilkinson TM, et al. Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2004, 170(4):400-407. doi:10.1164/rccm.200305-648OC.
[36]	Tulek B, Kivrak AS, Ozbek S, et al. Phenotyping of chronic obstructive pulmonary disease using the modified Bhalla scoring system for high-resolution computed tomography. Can Respir J, 2013, 20(2):91-96. doi:10.1155/2013/727523. pmid: 23616965
[37]	Narayana JK, Aliberti S, Mac Aogáin M, et al. Microbial Dysregulation of the Gut-Lung Axis in Bronchiectasis. Am J Respir Crit Care Med, 2023, 207(7):908-920. doi:10.1164/rccm.202205-0893OC.
[38]	Tan WC, Hague CJ, Leipsic J, et al. Findings on thoracic computed tomography scans and respiratory outcomes in persons with and without chronic obstructive pulmonary disease: a population-based cohort study. PLoS One, 2016, 11(11):e0166745. doi:10.1371/journal.pone.0166745.
[39]	Xie C, Wen Y, Zhao Y, et al. Clinical Features of Patients with Bronchiectasis with Comorbid Chronic Obstructive Pulmonary Disease in China. Med Sci Monit, 2019, 25:6805-6811. doi: 10.12659/MSM.917034 URL
[40]	Altenburg J, de Graaff CS, van der Werf TS, et al. Immunomodulatory effects of macrolide antibiotics-Part 2: Advantages and disadvantages of long-term, low-dose macrolide therapy. Respiration, 2011, 81(1):75-87. doi:10.1159/000320320. pmid: 20733282
[41]	Abate G, Blazevic A, et al. Enhancement of cellmediated immunity by antimycobacterial antibodies. Infect Immun, 2005, 73(10):6711-6720. doi:10.1128/IAI.73.10.6711-6720.2005.
[42]	Martínez-García MÁ, Soler-Cataluña JJ, DonatSanz Y, et al. Factors associated with bronchiectasis in patients with COPD. Chest, 2011, 140(5):1130-1137. doi:10.1378/chest.10-1758. pmid: 21546440
[43]	Martínez-García MA, de la Rosa Carrillo D, Soler-Cataluña JJ, et al. Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2013, 187(8):823-831. doi:10.1164/rccm.201208-1518OC.
[44]	Zhang RB, Yuan F, Tan XY, et al. Evaluation of symptoms and risks in stable chronic obstructive pulmonary disease patients with radiographic bronchiectasis. Chronic Dis Transl Med, 2017, 3(3):176-180. doi:10.1016/j.cdtm.2017.02.007.
[45]	Jin J, Yu W, Li S, et al. Factors associated with bronchiectasis in patients with moderate-severe chronic obstructive pulmonary disease. Medicine(Baltimore), 2016, 95(29):e4219. doi:10.1097/MD.0000000000004219.
[46]	McDonnell MJ, Jary HR, Perry A, et al. Non cystic fibrosis bronchiectasis:a longitudinal retrospective observational cohort study of pseudomonas persistence and resistance. Respir Med, 2015, 109(6):716-726. doi:10.1016/j.rmed.2014.07.021. pmid: 25200914
[47]	Kim KY, Lee HY, Yeo CD, et al. Factors Predicting Worse Outcomes in an Asian Cohort of Patients With Bronchiectasis. In Vivo, 2022, 36(6):2993-2998. doi:10.21873/invivo.13044. pmid: 36309393
[48]	Gursel G. Does coexistence with bronchiectasis influence intensive care unit outcome in patients with chronic obstructive pulmonary disease? Heart Lung, 2006, 35(1):58-65. doi:10.1016/j.hrtlng.2005.04.003. pmid: 16426936
[49]	Mateus SP, Ribeiro-Alves M, Salles REB, et al. Mortality and comorbidities in patients with bronchiectasis over a 3-year follow-up. Medicine (Baltimore), 2022, 101(52):e32537. doi:10.1097/MD.0000000000032537.
[50]	Martínez García Má, Soriano JB. Asthma, bronchiectasis, and chronic obstructive pulmonary disease: the Bermuda Triangle of the airways. Chin Med J (Engl), 2022, 135(12):1390-1393. doi:10.1097/CM9.0000000000002225.
[51]	Pascual-Guardia S, Amati F, Marin-Corral J, et al. Bacterial Patterns and Empiric Antibiotic Use in COPD Patients With Community-Acquired Pneumonia. Arch Bronconeumol, 2023, 59(2):90-100. doi:10.1016/j.arbres.2022.09.005.
[52]	Gershon AS, Thiruchelvam D, Aaron S, et al. Socioeconomic status (SES) and 30-day hospital readmissions for chronic obstructive pulmonary (COPD) disease: A population-based cohort study. PLoS One, 2019, 14(5):e0216741. doi:10.1371/journal.pone.0216741.
[53]	Poh TY, Tiew PY, Lim AYH, et al. Increased Chitotriosidase Is Associated With Aspergillus and Frequent Exacerbations in South-East Asian Patients With Bronchiectasis. Chest, 2020, 158(2):512-522. doi:10.1016/j.chest.2020.02.048. pmid: 32184111
[54]	Lei J, Yang T, Liang C, et al. Comparison of Clinical Characteristics and Short-Term Prognoses Within Hospitalized Chronic Obstructive Pulmonary Disease Patients Comorbid With Asthma, Bronchiectasis, and Their Overlaps: Findings From the ACURE Registry. Front Med (Lausanne), 2022, 9:817048. doi:10.3389/fmed.2022.817048.
[55]	毛贝. 慢性阻塞性肺疾病合并支气管扩张症临床特征及预后相关因素研究. 苏州: 苏州大学, 2016.
[56]	邹外龙, 闫磊, 张鑫, 等. 支气管扩张症合并慢性阻塞性肺疾病急性加重患者住院死亡的相关因素. 中华老年多器官疾病杂志, 2021, 20(8):590-594. doi:10.11915/j.issn.1671-5403.2021.08.123.
[57]	Choi H, Chalmers JD. Bronchiectasis exacerbation: a narrative review of causes, risk factors, management and prevention. Ann Transl Med, 2023, 11(1):25. doi:10.21037/atm-22-3437. pmid: 36760239
[58]	但小苹, 邱倩, 杨再兴, 等. 淋巴细胞微粒数目在慢性阻塞性肺疾病患者支气管肺泡灌洗液中的变化. 中国呼吸与危重监护杂志, 2014, 13(2):125-129. doi:10.7507/1671-6205.2014032.
[59]	Shen S, Yan X, Xu B. The blood urea nitrogen/creatinine (BUN/cre) ratio was U-shaped associated with all-cause mortality in general population. Ren Fail, 2022, 44(1):184-190.doi:10.1080/0886022X.2022.2030359. pmid: 35166184
[60]	Arihan O, Wernly B, Lichtenauer M, et al. Blood Urea Nitrogen (BUN) is independently associated with mortality in critically ill patients admitted to ICU. PLoS One, 2018, 13(1):e0191697.doi:10.1371/journal.pone.0191697.
[61]	Fendoğlu TZ, Köktürk N, Yapar D, et al. The effect of bronchiectasis on the exacerbation and mortality of chronic obstructive pulmonary disease. Clin Respir J, 2021, 15(10):1113-1120. doi:10.1111/crj.13417.
[62]	Serrano Gotarredona MP, Navarro Herrero S, Gómez Izquierdo L, et al. Smoking-related interstitial lung disease. Radiologia (Engl Ed), 2022, 64Suppl 3:277-289. doi:10.1016/j.rxeng.2022.10.008.
[63]	Guan WJ, Xu JF, Luo H, et al. A Double-Blind Randomized Placebo-Controlled Phase 3 Trial of Tobramycin Inhalation Solution in Adults With Bronchiectasis With Pseudomonas aeruginosa Infection. Chest, 2023, 163(1):64-76. doi:10.1016/j.chest.2022.07.007.
[64]	Sogbetun F, Eschenbacher WL, Welge JA, et al. A comparison of five surveys that identify individuals at risk for airflow obstruction and chronic obstructive pulmonary disease. Respir Med, 2016, 120:1-9. doi:10.1016/j.rmed.2016.09.010. pmid: 27817804
[65]	Llordés M, Zurdo E, Jaén á, et al. Which is the Best Screening Strategy for COPD among Smokers in Primary Care? 2017, 14(1):43-51. doi:10.1080/15412555.2016.1239703.
[66]	Spyratos D, Haidich AB, Chloros D, et al. Comparison of Three Screening Questionnaires for Chronic Obstructive Pulmonary Disease in the Primary Care. Respiration, 2017, 93(2):83-89. doi:10.1159/000453586. pmid: 28052294
[67]	Soriano JB, Molina J, Miravitlles M. Combining casefinding methods for COPD in primary care: a large, twostage design study. Int J Tuberc Lung Dis, 2018, 22(1):106-111. doi:10.5588/ijtld.17.0334. pmid: 29297434
[68]	Miravitlles M, Llor C, Calvo E, et al. Validation of the Spanish version of the Chronic Obstructive Pulmonary Disease Population Screener (COPDPS). Its usefulness and that of FEV₁/FEV₆ for the diagnosis of COPD. Med Clin (Barc), 2012, 139(12):522-530. doi:10.1016/j.medcli.2011.06.022. pmid: 22015009
[69]	Gu Y, Zhang Y, Wen Q, et al. Performance of COPD population screener questionnaire in COPD screening: a validation study and metaanalysis. Ann Med, 2021, 53(1):1198-1206. doi:10.1080/07853890.2021.1949486.
[70]	Hanania NA, Mannino DM, Yawn BP, et al. Predicting risk of airflow obstruction in primary care: Validation of the lung function questionnaire (LFQ). Respir Med, 2010, 104(8):1160-1170. doi:10.1016/j.rmed.2010.02.009. pmid: 20226647
[71]	Mintz ML, Yawn BP, Mannino DM, et al. Prevalence of airway obstruction assessed by lung function questionnaire. Mayo Clin Proc, 2011, 86(5):375-381. doi:10.4065/mcp.2010.0787. pmid: 21531880
[72]	Dalal AA, DemuroMercon C, Lewis S, et al. Validation of alternate modes of administration of the lung function questionnaire (LFQ) in subjects with smoking history. Int J Chron Obstruct Pulmon Dis, 2010, 5:425-434. doi:10.2147/COPD.S13900.
[73]	Martinez FJ, Mannino D, Leidy NK, et al. A New Approach for Identifying Patients with Undiagnosed Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med, 2017, 195(6):748-756. doi:10.1164/rccm.201603-0622OC.
[74]	Leidy NK, Martinez FJ, Malley KG, et al. Can CAPTURE be used to identify undiagnosed patients with mildtomoderate COPD likely to benefit from treatment? Int J Chron Obstruct Pulmon Dis, 2018, 13:1901-1912. doi:10.2147/COPD.S152226.
[75]	Weiss G, Steinacher I, Lamprecht B, et al. Development and validation of the Salzburg COPDscreening questionnaire (SCSQ): a questionnaire development and validation study. NPJ Prim Care Respir Med, 2017, 27(1):4. doi:10.1038/s41533-016-0005-7.
[76]	Ritchie AI, Singayagam A, Mitchell S, et al. The Effect of Inhaled Corticosteroids on Pneumonia Risk in Patients With COPD-Bronchiectasis Overlap: A UK Population-Based Case-Control Study. Chest, 2023, 164(4):875-884. doi:10.1016/j.chest.2023.06.007. pmid: 37419145